Not available
Quote | Incyte Corporation (NASDAQ:INCY)
Last: | $52.05 |
---|---|
Change Percent: | 0.25% |
Open: | $52 |
Close: | $51.92 |
High: | $52.2175 |
Low: | $51.39 |
Volume: | 1,036,287 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | Incyte Corporation (NASDAQ:INCY)
2024-04-23 07:31:43 ET More on Incyte Incyte: A Potential GARP Superstar Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript Incyte Corporation 2023 Q4 - Results - Earnings Call Presentation Incyte and CMS collaborate for povorcitinib in Mainland China...
EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria E...
Message Board Posts | Incyte Corporation (NASDAQ:INCY)
Subject | By | Source | When |
---|---|---|---|
$INCY bears are running | chmcnfunds | investorshub | 05/01/2023 6:42:04 AM |
Price now | chmcnfunds | investorshub | 04/27/2023 4:15:20 PM |
short squeeze article | ValueInvestor15 | investorshub | 04/27/2023 9:03:03 AM |
$INCY What do you make of this? | $Pistol Pete$ | investorshub | 04/25/2023 12:51:51 PM |
Found an interesting article | TREND1 | investorshub | 04/22/2023 10:50:51 PM |
News, Short Squeeze, Breakout and More Instantly...
EP262, a first-in-class oral Mas-related G protein-coupled receptor X2 (MRGPRX2) antagonist with the potential to treat a broad range of inflammatory disorders, has demonstrated proof-of-mechanism in chronic inducible urticaria and is in a Phase 2 study for chronic spontaneous urticaria E...
2024-04-12 12:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria Incyte (Nasdaq:INCY) (“I...